Full-Time

Employee Health Services Senior Director

Primary Care Clinic Physician

Posted on 5/9/2026

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$178.5k - $261.8k/yr

+ Bonus

Indianapolis, IN, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • MD/DO board-certified in Internal Medicine or Family Medicine
  • Active, unrestricted Indiana medical license and willingness to obtain medical license in other states
  • Active Indiana Controlled Substance Registration (CSR) and DEA license with prescriptive authority
Responsibilities
  • Deliver comprehensive adult primary care, including annual preventive exams, health screenings, acute episodic care, and chronic disease management
  • Diagnose, treat, and manage chronic conditions using a longitudinal care model
  • Provide timely care for acute medical concerns
  • Offer basic gynecologic care, including contraceptive counseling, menstrual and menopause health management, and routine pelvic and breast exams
  • Administer and counsel patients on CDC-recommended and age-appropriate vaccinations
  • Educate employees on preventive strategies, self-monitoring tools, and evidence-based interventions that support healthspan and well-being
  • Practice in a model that prioritizes time-rich visits and removes the pressure of volume or RVU-based productivity
  • Collaborate with onsite advanced practice providers (nurse practitioners and physician assistants), mental health professionals, care coordinators, and specialists to deliver integrated, team-based care
  • Engage in case discussions for complex or high-risk patients, facilitating internal referrals and external specialty connections when appropriate
  • Use biometric data, lab trends, wearable device outputs, and risk assessments to inform personalized clinical decisions
  • Participate in group learning sessions, journal clubs, and continuous improvement activities to maintain clinical excellence
  • Coordinate care with external subspecialty providers, ensuring seamless medical treatment for patients requiring consultation
  • Serve as a trusted physician and advocate for employee patients, focusing on building meaningful, long-term relationships
  • Deliver inclusive, equitable care that respects the diverse backgrounds, identities, and health beliefs of all employees
  • Support company-wide health initiatives and collaborate with wellness teams to integrate primary care into broader well-being strategies
  • Maintain accurate, timely, and confidential documentation in the electronic health record
  • Comply with OSHA, ADA, privacy, and workplace safety regulations and participate in relevant clinical policy programming
  • Participate in call rotation to ensure after-hours medical support for employees
  • Other duties within scope of clinical practice as requested by the Senior Director, Employee Health Services
Desired Qualifications
  • 2 years of experience post residency
  • Demonstrated commitment to patient-centered, inclusive care
  • Demonstrated experience providing adult primary care in an outpatient clinic setting
  • Experience with employer-based clinics, population health, or corporate wellness programs
  • Experience in direct primary care or advanced primary care models
  • Knowledge of EHRs, wearable data, and digital health tools
  • Interest in lifestyle medicine and health behavior change
  • BLS and ACLS certification or willingness to obtain
  • Willingness to participate in shared after-hours call responsibilities and offer early/late patient access when needed

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • Mounjaro generates $8.66B Q1 2026 sales, surpassing Keytruda as world's top drug.
  • International Mounjaro revenue surges to $4.4B in Q1 2026 from China's reimbursement list.
  • $21B LEAP district investment opens first genetic medicine facility on May 6, 2026.

What critics are saying

  • Novo Nordisk's CagriSema achieves 22.7% weight loss, eroding tirzepatide share in 6-12 months.
  • Compounding pharmacies divert 25% GLP-1 prescriptions, slashing $10B annual revenue now.
  • Pfizer's danuglipron oral Phase 3 data halves injectable dominance in 12-18 months.

What makes Lilly USA unique

  • Foundayo delivers 11% weight loss as once-daily oral GLP-1 pill approved April 1, 2026.
  • Lebanon API facility launches 2027 as largest U.S. site producing tirzepatide and orforglipron.
  • $2.25B Profluent Bio deal develops AI-driven kilobase-scale DNA editing for genetic diseases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lilly USA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.